Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias

• Published in: Alzheimer's research & therapy Vol. 14; no. 1; pp. 153 - 12
• Main Authors: Baiardi, Simone, Quadalti, Corinne, Mammana, Angela, Dellavalle, Sofia, Zenesini, Corrado, Sambati, Luisa, Pantieri, Roberta, Polischi, Barbara, Romano, Luciano, Suffritti, Matteo, Bentivenga, Giuseppe Mario, Randi, Vanda, Stanzani-Maserati, Michelangelo, Capellari, Sabina, Parchi, Piero
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 12.10.2022; BioMed Central; BMC
• Subjects: alpha-Synuclein; Alzheimer disease; Alzheimer Disease - cerebrospinal fluid; Alzheimer's disease; Amyloid beta-Peptides - cerebrospinal fluid; Biomarkers; Biomarkers - cerebrospinal fluid; Care and treatment; Cellular proteins; Cerebrospinal fluid; Corticobasal syndrome; Dementia; Diagnosis; Frontotemporal dementia; Frontotemporal Dementia - cerebrospinal fluid; Frontotemporal Dementia - diagnosis; FTLD; Genetic aspects; Glial Fibrillary Acidic Protein; Health aspects; Humans; Identification and classification; Lewy bodies; Medical diagnosis; Neurodegeneration; Pathology; Progressive supranuclear palsy; tau Proteins - cerebrospinal fluid; Italy; United States > US; Alzheimer disease; Progressive supranuclear palsy; FTLD; Tau; Frontotemporal dementia; Alpha-synuclein; Corticobasal syndrome; Lewy bodies; RT-QuIC

Increasing evidence supports the use of plasma biomarkers of neurodegeneration and neuroinflammation to screen and diagnose patients with dementia. However, confirmatory studies are required to demonstrate their usefulness in the clinical setting. We evaluated plasma and cerebrospinal fluid (CSF) sa...